Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Innate Pharma S.A.NASDAQ: IPHA

Operating Income · Q4 FY2025 · quarter ended Dec 2025

Operating income remains negative

Q4 FY2025 operating income was -€28M, compared with -€25.26M a year earlier.

Context

  • Operating income amounted to 1916.9% of revenue in FY2025, up 1508.3 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 3 analysts of -€4.31M (+91.9%) for the fiscal year ending Dec 2026, a step up from the -3.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-€28M— QoQ
Last fiscal yearDec 2025
-€53.43M-3.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.8%——
1 year-3.6%+91.9%+95.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

EUR · from the income statement

Latest · FY2025
(53.43M) EUR
Year-over-year change
-3.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.6% is the 6th highest of 9, against a peer median of +5.5%.
  • Operating income amounts to 1916.9% of revenue for IPHA, versus a peer median of 2381.2%.
IPHA Competitors
Operating Income for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$30.7M USD+307.5%—42.3%
NVCTNuvectis Pharma, Inc.LTM Mar 2026-$28.27M USD-34.5%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$34.64M USD+32.5%—1093.0%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.58M USD+17.4%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$47.43M USD+9.0%—9033.9%
IPHAInnate Pharma S.A.FY2025-€53.43M EUR-3.6%—1916.9%
MOLNMolecular Partners AGLTM Mar 2026-CHF 61.98M CHF+2.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$65.46M USD-25.5%—3669.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$89.84M USD-52.6%——
Peer median (excluding IPHA) —+5.5%—2381.2%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.